NEMIC Co-Founder Takes International Stage During BIO 2024
SAN DIEGO, Calif. — The sun wasn’t the only thing shining bright in California earlier this month. Rhode Island’s robust life sciences ecosystem, NEMIC, and one of our co-founders were also putting on a dazzling display at the annual BIO International Convention in San Diego.
The BIO International Convention is the largest and most comprehensive event for biotechnology and life science, with more than 18,500 industry leaders from across the globe representing a wide breadth of sectors, including but not limited to drug developers, startup companies, large corporations, manufacturing organizations, and national pavilions. NEMIC was once again invited to attend the event and share event space with Rhode Island Commerce and the Rhode Island Life Science Hub. It was the first industry-facing convention for the newly formed RILSH, and NEMIC and RI BIO were on hand to help the organization stake Rhode Island’s claim as a formal industry player in the international landscape.
At the Korean Pavilion, The Korea Institute of Toxicology (KITox) tapped NEMIC Co-Founder and Managing Partner Lydia Shin to not only speak on behalf of NEMIC, but also as a global advisor and representative expert in HealthTech commercialization. She spoke to an audience of 34+ Korean startups about key industry topics such as the commercialization process of US market entry, investor profile considerations, and funding opportunities in Rhode Island for international companies.
This seminar dovetails off of NEMIC’s 2023 Memorandum of Understanding (MOU) with KITox, which aims to develop commercial opportunities with a key player within Korea’s massive Life Science ecosystem. It also demonstrates NEMIC and Rhode Island’s commitment to partnering with both Korean Government-funded organizations and international startups, as well as our deep commitment to fostering innovation in the state of Rhode Island, and growing far-reaching partnerships that transform healthcare to improve outcomes worldwide.
ABOUT KITox
Part of Korea’s National Research Council of Science and Technology(NST), the Korea Institute of Toxicology–KITox–is a government-funded institute. KITox is a world-class nonclinical contract research organization, certified by Korean and international authorities based on OECD and US FDA GLP criteria. Established in 1980, KITox is revered for its pioneering efforts in toxicological research and its relentless commitment to improving public health and safety.